Compound
1 ml nasal spray contains:
Active substance:
Xylometazoline hydrochloride 0.5 mg or 1.0 mg
Excipients:
Sea water - 250.0 mg,
Potassium dihydrogen phosphate - 0.45 mg,
Purified water - 754.35 mg or 753.85 mg.
The theoretical total weight is 1005.3 mg.
pharmachologi effect
Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores the patency of the nasal passages, facilitates nasal breathing.
The effect of the drug occurs 5-10 minutes after its application and lasts up to 12 hours.
Indications
acute respiratory diseases with symptoms of rhinitis (runny nose);
acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa);
to facilitate rhinoscopy and other diagnostic manipulations in the nasal passages.
Use during pregnancy and lactation
Contraindicated in pregnancy, breastfeeding with caution.
Contraindications
Hypersensitivity;
arterial hypertension;
tachycardia;
severe atherosclerosis;
glaucoma;
atrophic rhinitis;
thyrotoxicosis;
surgical interventions on the meninges (in history);
pregnancy;
children's age up to 6 years (for 0.1% solution);
children's age up to 2 years (for 0.05% solution).
With caution: lactation period, coronary heart disease (angina pectoris), prostatic hyperplasia, diabetes mellitus
Side effects
Classification of the frequency of occurrence of adverse reactions: very often (> 1/10); often (> 1/100 to < 1/10); infrequently (> 1/1000 to < 1/100); rare (> 1/10,000 to < 1/1,000); very rarely (< 1/10000).
From the immune system:
Very rare: hypersensitivity reactions (angioedema, rash, itching).
From the nervous system:
Often: headache.
Rarely: insomnia, depression (with prolonged use in high doses).
Very rare: restlessness, fatigue, paresthesia, hallucinations and convulsions (mainly in children).
From the sense organs:
Very rare: impaired visual clarity.
From the side of the cardiovascular system:
Rarely: palpitations, increased blood pressure.
Very rare: tachycardia, arrhythmia.
From the respiratory system:
Often: irritation and / or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa.
Rarely: after the use of the drug, there may be an increase in swelling of the nasal mucosa (reactive hyperemia), bleeding from the nose.
From the digestive system
Often: nausea.
Rare: vomiting.
Local reactions:
Often: burning at the site of application.
If you experience side effects that are listed in the instructions or they get worse, or you notice any other side effects that are not listed in the instructions, tell your doctor.
Interaction
Simultaneous use of xylometazoline with monoamine oxidase (MAO) inhibitors, tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants), and
also other drugs that increase blood pressure, can lead to an increase in blood pressure, so the simultaneous use of these drugs is contraindicated.
If you are using any of the medicines listed above or any other medicines (including OTC medicines), talk to your doctor before taking Snoop®.
How to take, course of administration and dosage
Intranasally.
Children aged 2 to 6 years: 1 injection in each nostril (if necessary, can be repeated), up to three times a day.
Adults and children over 6 years: 2 sprays in each nostril, up to three times a day.
The drug should not be used more than 3 times a day, the duration of the course is not more than 7 days.
Before use, clean the nasal passages.
Remove protective cap. Before the first use, press the rim of the spray nozzle several times until a uniform cloud of "fog" appears. The bottle with the drug is ready for further use.
When using the nozzle, insert it into the nasal cavity and press once on the rim. Keep the bottle upright.
Do not spray horizontally or downwards. Immediately after the injection, it is recommended to take a light breath through the nose. After use, close the vial with a protective cap.
Each vial must be used individually.
After completion of therapy, the drug can be re-administered only after a few days.
Regarding the duration of use in children, consult a doctor.
In the case of chronic rhinitis, Snoop® 0.05% and 0.1% can only be used under medical supervision, given the risk of atrophy of the nasal mucosa.
If there is no improvement after treatment, or symptoms worsen, or new symptoms appear, you should consult your doctor.
